Placebo-controlled trial of high-dose Mesterolone treatment of idiopathic male infertility.

Abstract

The possible effect of Mesterolone (Schering N.V., Brussels, Belgium) (1 alpha-methyl-5-alpha-androstane-17 beta-ol-3-one) on semen quality and fertility of men with idiopathic oligoasthenospermia and/or teratozoospermia has been evaluated in a double-blind trial. The study included 52 patients who were treated during 12 months with either 150 mg/d of Mesterolone or placebo. The overall pregnancy rate was similar in the Mesterolone-treated cases (26%) and in the placebo control cases (48%), although a significant increase in motility and in the proportion of spermatozoa with normal morphology was recorded in the Mesterolone-treated cases. Because similar semen improvement also occurred in the placebo controls, our findings cast doubt on the possible usefulness of high-dose Mesterolone treatment of idiopathic male infertility.

• Authors: J Gerris, F Comhaire, P Hellemans, K Peeters, F Schoonjans
• Journal: Fertility and sterility (Fertil Steril) Vol. 55 Issue 3 Pg. 603-7 (Mar 1991) ISSN: 0015-0282 [Print] United States
• PMID: 1900485 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Dihydrotestosterone
• Mesterolone
• Testosterone
• Estradiol
• Luteinizing Hormone
• Follicle Stimulating Hormone

Topics

• Administration, Oral
• Dihydrotestosterone (blood)
• Double-Blind Method
• Estradiol (blood)
• Follicle Stimulating Hormone (blood)
• Humans
• Infertility, Male (drug therapy)
• Luteinizing Hormone (blood)
• Male
• Mesterolone (pharmacology)
• Semen (drug effects)
• Sperm Count (drug effects)
• Sperm Motility (drug effects)
• Testosterone (blood)
• Time Factors